Targeting Chromosomal Instability and Mitotic Signaling as Therapeutic Vulnerabilities in Glioblastoma
Recent research indicates that chromosomal instability (CIN) and aneuploidy create distinct stress dependencies in cancer cells, providing actionable targets for drug intervention. Among the various therapeutic candidates, the small-molecule inhibitor tozasertib has garnered attention for its ability to target mitotic pathways, offering a potential strategy to overcome therapy resistance. To better understand the genetic landscape of these vulnerabilities, researchers often utilize resources like BioGRID to map protein-interaction networks that regulate mitotic fidelity.
The therapeutic landscape for glioblastoma (GBM) is rapidly evolving, with a focus on modulating mitotic kinases and spindle assembly checkpoint (SAC) components. The following table summarizes key therapeutic agents currently under investigation for their role in targeting CIN and mitotic regulatory pathways:
| Therapeutic Category | Target/Mechanism | Potential Clinical Impact |
|---|---|---|
| Mitotic Kinase Inhibitors | Nek2, Plk4 | Selectively induces apoptosis in cells with centrosome amplification. |
| SAC Regulators | MPS1, BUB3 | Enhances sensitivity to radiation and chemotherapy by disrupting mitotic fidelity. |
| DDR Pathway Inhibitors | ATR, ATM, PARP | Exploits inherent genomic instability to prevent DNA damage repair. |
| Autophagy Modulators | p62/SQSTM1 | Regulates micronuclear stability and modulates tumor immunogenicity. |
Furthermore, the integration of targeted therapies with novel approaches like CAR T-cell therapy offers a synergistic path toward improving patient outcomes. By exploiting the genomic stress profiles of tumors, such as those documented in comprehensive databases like the ChEMBL database , clinicians may be able to better predict treatment responses. Emerging evidence suggests that modulating cytoplasmic stress through p62-dependent mechanisms or employing genome-engineering tools like KaryoCreate provides deeper insights into the drivers of CIN. Despite these advancements, challenges such as the lack of standardized clinical metrics for CIN and the inherent spatial heterogeneity of glioblastoma remain critical barriers that must be addressed to facilitate successful clinical translation.